Midday movers: Apple, McDonald's, NeuStar & More

NYSE EuroNext flag hangs outside the NYSE.
Adam Jeffery | CNBC
NYSE EuroNext flag hangs outside the NYSE.

Take a look at some of Monday's midday movers:

Achillion Pharmaceuticals - The hepatitis C drug developer surged on speculation it could be taken over.

Allergan - Shares of the Botox maker fell after activist investor Bill Ackman, speaking on CNBC, said Allergan shareholders told him they would support a deal at $180 a share. Ackman and Valeant Pharmaceuticals International are in the midst of a hostile takeover of Allergan.

Apple -The iPhone maker gained in its first session after a seven-for-one stock split.

Capital One Financial - The credit card issuer climbed after Nomura upgraded the stock to buy from neutral.

Family Dollar Stores - The discount retailer gained after adopting a one-year poison pill with a trigger of 10 percent, after Carl Icahn reported a 9.4 percent stake in the company, making him its largest shareholder.

Gilead Sciences - The drug developer fell after news that Merck was entering the hepatitis C market with its acquisition of Idenix Pharmaceuticals. Piper Jaffray said Merck could be in stronger position for its patent litigation against Gilead's hepatitis C Sovaldi drug.

McDonald's - The fast-food chain fell after reporting another month of disappointing sales in the United States.

Morgan Stanley - The bank gained on news it is selling its controlling stake in pipeline firm TransMontaigne to NGL Energy Partners for $200 million.

NeuStar - The provider of technology and directory services fell on reports it could lose a phone contract to rival Ericsson, citing an email made public on a government website.

Office Depot - The retailer gained on a positive article in Barron's, which said shares could rise over 50 percent.

Pilgrim's Pride - The poultry producer declined after it lost out to Tyson Foods in its attempt to buy Hillshire Brands.

(Read More: See CNBC's Market Insider Blog)

—By CNBC's Rich Fisherman.

Questions? Comments? Email us at marketinsider@cnbc.com